Cystic Fibrosis Foundation issued the following clinical trial alerts in the month of September.
September 17, 2019
Study of QBW276 in adults with CF
Status: Completed with results
Description: This study evaluated the safety and tolerability of QBW276, an inhaled drug designed to improve mucus clearance. This study also evaluated how the body processes the drug.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40 to 100%
Number of Visits: 6
Length of Participation: 14 days
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02566044
Study of adherence to lumacaftor/ivacaftor using a smart pill bottle device
Status: Completed with results
Description: This study evaluated the impact of a smart pill bottle device on adherence to lumacaftor/ivacaftor (Orkambi®).This study was for people with CF who were not currently being treated with lumacaftor/ivacaftor (Orkambi®) prior to enrolling in the study.
Age: 16 Years and Older
Mutation: Two Copies F508del
Fev1% Predicted: 40% or greater
Number of Visits: 7
Length of Participation: 48 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02823470
Study of VX-661 plus ivacaftor in people with CF who have two copies of the F508del CFTR mutation
Status: Completed with results
Description: This study evaluated the safety and effectiveness of the CFTR modulator drug VX-661 in combination with ivacaftor (Symdeko®). This study was for people with CF who have two copies of the F508del CFTR mutation.
Age: 18 Years and Older
Mutation: Two Copies F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 6
Length of Participation: 60 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02508207